Targeting the genesis of chronic disease with novel hydrogel technology
By targeting the GI pathway, Gelesis has the potential to transform how chronic diseases are treated. In contrast with existing approaches that treat symptoms, Gelesis targets GI-related diseases at their source cause.
The Gelesis Platform
Inducing satiety to reduce caloric intake and induce weight loss
Improving glycemic control
Reducing inflammation associated with GI disorders
The proprietary Gelesis platform is the first and only superabsorbent hydrogel made exclusively from naturally-derived food ingredients.
Products developed with the novel Gelesis hydrogel platform are designed to be non-systemic, non-stimulant and not absorbed by the body. FDA has designated the components of the hydrogel as GRAS, or Generally Recognized as Safe
Hydrogel volume limited to fluids present in the GI tract, as well as hydration capacity of the hydrogel
Reducing Risk of Obstruction
Small particles do not stick together and have similar elastic response as ingested solid foods
Reducing Risk of Dehydration or Diarrhea
Digestive enzymes in the large intestine degrade 3D structure, releasing water, which is reabsorbed by the body
The most common side effects observed in clinical trials with Gelesis100/GS200 were gastrointestinal symptoms like bloating, flatulence, abdominal pain, or diarrhea.